NEW PRODUCT: COGNIVAID™
Moleac has just launched a new product, CognivAiD™, in Singapore!
A Focus on Neurology
Since Moleac was founded, our ambition is to provide new solutions to supplement the therapeutic armamentarium for conditions where significant unmet needs remain. To achieve this goal, we develop natural products according to international standards and commercialize our products worldwide.
Our products are developed by Moleac with scientific excellence and evidence-based approach.
Together with our R&D department and world renowned experts, we have successfully developed and marketed NeuroAiD, the world’s first post-stroke recovery treatment, helping patients to regain functional independence after a stroke or a traumatic brain injury by amplifying endogenous processes of brain repair. NeuroAiD is available in over 30 countries worldwide.
A growing international network
Patients taking NeuroAid yearly
Awards
Countries with Exclusive Partnership
Moleac wins SBR National Business Awards 2021 under Pharmaceutical Category.
Moleac wins SBR National Business Awards 2021 under Pharmaceutical Category.
Moleac has pioneered a new drug development approach that looks at sources of innovation from natural medicine, thus considerably shortening drug development cycle time and investment to bring medicine to post-stroke recovery patients.
Building on this success, the company expanded their worldwide presence from Singapore and developed a new herbal formulation (MLC1501) in post-stroke recovery. An Investigational New Drug application (IND) has been opened by US-Food and Drug Administration (USFDA), which allowed them to conduct two safety studies of MLC1501 in healthy volunteers (Phase 1). With an overall clinical development plan that hypothesizes MLC1501’s effectiveness in improving functional and motor independence and recovery of neurological impairments in post-AIS survivors having not received or not recovered after acute treatments (thrombolysis, thrombectomy).
Latest News
NEUROAID™II HOLDS PROMISE AS A SAFE ADD-ON THERAPY TO STANDARD ALZHEIMER DISEASE SYMPTOMATIC TREATMENTS AND MAY HAVE A DISEASE MODIFYING EFFECT BY DELAYING DISEASE PROGRESSION
Moleac is pleased to announce the release of the ATHENE study…
Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)¹.
Moleac, a biopharmaceutical company based in Singapore, wins SBR National….
Embracing World Stroke Day 2021
Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place…
MOLEAC ANNOUNCES US FDA APPROVAL OF IND APPLICATION FOR PHASE 1 STUDY OF MLC1501 PROGRAMME IN POST-TRAUMATIC BRAIN INJURY RECOVERY
Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new…
